Stefanie Flückiger-Mangual

PIQUR Therapeutics (Switzerland) — Switzerland

Biochemistry, Genetics and Molecular Biology · Life Sciences

1h-index127citations21works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(11), Cancer, Lipids, and Metabolism(6), Click Chemistry and Applications(5), Inflammatory mediators and NSAID effects(4), Nanoplatforms for cancer theranostics(4)

Publications21 total

978P Clinical activity of TT125-802, a highly selective bromodomain inhibitor of CBP/p300, in advanced solid tumors: Update on the ongoing phase I study
Annals of Oncology·2025
TT125-802, a highly selective, well-tolerated bromodomain inhibitor of CBP/p300 with anti-tumor activity in patients with advanced solid tumors: An update on the ongoing phase I study.
Journal of Clinical Oncology·2025
121 (PB109): TT125-802, a highly selective bromodomain inhibitor of CBP/p300, in patients with advanced solid tumors: an update on the phase I study
European Journal of Cancer·2024
A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of TT125-802 in patients with advanced solid tumors.
Journal of Clinical Oncology·2024
Abstract 5891: An image-based phenotypic screen identified CBP/p300 as new cancer drug resistance target and enabled the development of the clinical candidate TT125-802
Cancer Research·2024
Abstract 3907: Targeting adaptive resistance to EGFR and KRAS G12C inhibitors by TT125-802, a novel and specific CBP/p300 bromodomain inhibitor
Cancer Research·2023
Abstract 6268: TT125-802 is a potent and highly selective CBP/p300 bromodomain inhibitor for the treatment of castration resistant prostate cancer and haematological malignancies
Cancer Research·2023
Table S1 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i>-mutated Melanoma to MAPK Inhibitors
2023Open Access
Table S5 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i>-mutated Melanoma to MAPK Inhibitors
2023Open Access
Table S3 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i>-mutated Melanoma to MAPK Inhibitors
2023Open Access
Table S1 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i>-mutated Melanoma to MAPK Inhibitors
2023Open Access
Data from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i>-mutated Melanoma to MAPK Inhibitors
2023Open Access
Supplementary Data from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i>-mutated Melanoma to MAPK Inhibitors
2023Open Access
Supplementary Data from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i>-mutated Melanoma to MAPK Inhibitors
2023Open Access
Table S5 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i>-mutated Melanoma to MAPK Inhibitors
2023Open Access
Data from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i>-mutated Melanoma to MAPK Inhibitors
2023Open Access
Table S3 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i>-mutated Melanoma to MAPK Inhibitors
2023Open Access
Dynamic changes of genomic and transcriptomic tumor diversity during melanoma progression
2021Open Access
A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i> -mutated Melanoma to MAPK Inhibitors
Clinical Cancer Research·2019· 126 citedOpen Access
PO-241 Targeting fatty acid oxidation and glycolysis to overcome drug resistance to MAPK inhibitors
ESMO Open·2018· 1 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Wilhelm Krek(13), Andrea Aloia(12), Daniela Müllhaupt(12), Christophe D. Chabbert(12), Anja Irmisch(12), Reinhard Dummer(12), Werner J. Kovacs(12), Tanja Eberhart(11), Ana Vukolic(11), Ossia M. Eichhoff(11), Leila T. Alexander(11), Ernesto Scibona(11), Dennie T. Frederick(11), Benchun Miao(11), Chaoran Cheng(11), Lawrence N. Kwong(11), Zhi Wei(11), Genevieve M. Boland(11), Meenhard Herlyn(11), Keith T. Flaherty(11)